Physician profile
Matthew Johnson
NPI 1679157630
$1,545.85
in general payments reported to CMS, 2019-2025
13 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $301 · 2023: $304 · 2024: $104 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028 · Education: $154 · Travel and Lodging: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.42 |
| Education | $154.00 |
| Travel and Lodging | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.87 | 2022-2025 | |
| Ucb, INC. | $295.88 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $199.64 | 2025 | Cabtreo, Arazlo, Siliq |
| Arcutis Biotherapeutics, INC. | $118.77 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $95.46 | 2022 | |
| Galderma Laboratories, L.P. | $93.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $83.66 | 2025 | |
| Dermavant Sciences, INC. | $76.20 | 2024 | Vtama |
| Pfizer INC. | $56.49 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $29.25 | 2022 | |
| Incyte Corporation | $27.68 | 2024 | Opzelura |
| Genzyme Corporation | $18.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.